Remdesivir against COVID-19 and other viral diseases

JJ Malin, I Suárez, V Priesner… - Clinical microbiology …, 2020 - Am Soc Microbiol
Patients and physicians worldwide are facing tremendous health care hazards that are
caused by the ongoing severe acute respiratory distress syndrome coronavirus 2 (SARS …

[HTML][HTML] Pharmaceutical compounds used in the COVID-19 pandemic: A review of their presence in water and treatment techniques for their elimination

CA Morales-Paredes, JM Rodríguez-Díaz… - Science of the Total …, 2022 - Elsevier
During the COVID-19 pandemic, high consumption of antivirals, antibiotics, antiparasitics,
antiprotozoals, and glucocorticoids used in the treatment of this virus has been reported …

[HTML][HTML] Remdesivir for the treatment of COVID‐19

F Grundeis, K Ansems, K Dahms… - … of systematic reviews, 2023 - ncbi.nlm.nih.gov
Background Remdesivir is an antiviral medicine approved for the treatment of mild‐to‐
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …

Coronavirus disease 2019 as cause of viral sepsis: a systematic review and meta-analysis

E Karakike, EJ Giamarellos-Bourboulis… - Critical care …, 2021 - journals.lww.com
Objective: Coronavirus disease 2019 is a heterogeneous disease most frequently causing
respiratory tract infection, which can induce respiratory failure and multiple organ …

SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19

I Vicenti, M Zazzi, F Saladini - Expert Opinion on Therapeutic …, 2021 - Taylor & Francis
ABSTRACT Introduction: The current SARS-CoV-2 pandemic urgently demands for both
prevention and treatment strategies. RNA-dependent RNA-polymerase (RdRp), which has …

An overview on the treatments and prevention against COVID-19

Y Panahi, AM Gorabi, S Talaei, F Beiraghdar… - Virology Journal, 2023 - Springer
Background The coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …

Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis

A Rezagholizadeh, S Khiali, P Sarbakhsh… - European journal of …, 2021 - Elsevier
Abstract The coronavirus disease 2019 (COVID-19) pandemic has become a global health
crisis. Considering the recent food and drug administration (FDA) approval of remdesivir as …

Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence

HXJ Lin, S Cho, V Meyyur Aravamudan, HY Sanda… - Infection, 2021 - Springer
COVID-19 is an infectious disease caused by a novel β-coronavirus, belonging to the same
subgenus as the Severe Acute Respiratory Syndrome (SARS) virus. Remdesivir, an …

Prenatal exposure to perfluoroalkyl substances associated with increased susceptibility to liver injury in children

N Stratakis, DV Conti, R Jin, K Margetaki, D Valvi… - Hepatology, 2020 - journals.lww.com
The severe acute respiratory syndrome coronavirus 2 pandemic has drastically altered all
facets of clinical care and research. Clinical research in hepatology has had a rich tradition …

Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis

EL Fu, RJ Janse, Y de Jong… - Clinical kidney …, 2020 - academic.oup.com
Background Acute kidney injury (AKI) can affect hospitalized patients with coronavirus
disease 2019 (COVID-19), with estimates ranging between 0.5% and 40%. We performed a …